A doctor produces $96,000 monthly with a 22% ProSal rate, but her cases use unusually high outside-lab and drug costs. Her gross revenue looks strong while contribution margin is lower than peers. Which compensation review is most appropriate? The same trend appears in the trailing 12-month dashboard, not just in one unusual month.
